WO2007063824A1 - 放射性ハロゲン標識有機化合物の前駆体化合物 - Google Patents
放射性ハロゲン標識有機化合物の前駆体化合物 Download PDFInfo
- Publication number
- WO2007063824A1 WO2007063824A1 PCT/JP2006/323659 JP2006323659W WO2007063824A1 WO 2007063824 A1 WO2007063824 A1 WO 2007063824A1 JP 2006323659 W JP2006323659 W JP 2006323659W WO 2007063824 A1 WO2007063824 A1 WO 2007063824A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituent
- carbon atoms
- group
- branched
- compound
- Prior art date
Links
- CEPJFPAPEUWUGH-IXDOHACOSA-N CCOC([C@@H]([C@H](C1)C[C@H]1OCc1ccccc1)NC(OC(C)(C)C)=O)=O Chemical compound CCOC([C@@H]([C@H](C1)C[C@H]1OCc1ccccc1)NC(OC(C)(C)C)=O)=O CEPJFPAPEUWUGH-IXDOHACOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a precursor compound that can be suitably used for the production of a radiohalogen-labeled organic compound, which is an effective component of a diagnostic agent for positron emission tomography and single-photon emission tomography.
- Nuclear medicine examinations represented by positron emission tomography (hereinafter referred to as PET) and single photon emission tomography (hereinafter referred to as SPE CT) It is effective for diagnosis of various diseases including heart disease and cancer. These methods are methods of administering a drug labeled with a specific radioisotope (hereinafter referred to as “radiopharmaceutical”) and detecting ⁇ -rays released directly or indirectly from the drug. .
- Radiopharmaceutical a specific radioisotope
- Nuclear medicine testing has a high specificity and sensitivity to disease V, and has excellent properties! / If it is possible to obtain information on the function of the lesion, it is possible to obtain other tests. The method has its own characteristics.
- 18 F- FDG [ 18 F] 2 -Fluoro 2 -Deoxy- D-glucose
- nuclear medicine examination is a method performed by tracking the distribution of administered radiopharmaceuticals
- the information obtained varies depending on the nature of the radiopharmaceutical.
- radiopharmaceuticals for various diseases have been developed, and some have been clinically applied.
- various tumor diagnostic agents, blood flow diagnostic agents, receptor mapping agents and the like have been developed.
- [ 18 F] FACBC radiohalogen-labeled amino acids
- the compound is designed and studied for clinical application (Patent Document 1, Non- Patent Document 1, Non-Patent Document 2). Since [ 18 F] FACBC has the property of being specifically incorporated into amino acid transporters, it is considered to be effective as a diagnostic agent for tumors with high growth ability.
- FACBC is prepared by the following method: 1— (N— (t-butoxycarbol) amino) 3— [(((trifluoromethyl) sulfo-oxy) oxy] -cyclobutane 1 A method is disclosed in which deprotection is carried out by substituting the triflate group at the 3-position with radioactive fluorine and giving an acidic condition thereto (Patent Document 1, Non-Patent Document 1, Non-Patent Document 1, Patent Document 2).
- Patent Document 1 Japanese Translation of Special Publication 2000-500442
- Non-Patent Document 2 Timothy M. Shoup et al., Synthesis and Evaluation of [18F] 1- Amino-3-fluorocyclobutane- 1-carboxylic Acid to Image Brain Tumors. ", The Journal of Nuclear Medicine, 1999, 40, p.331—338
- Methanol is designated as a Class 2 solvent in the ICH “Regarding Residual Solvent Guidelines for Pharmaceuticals” and is treated as a solvent that should be regulated for residues in pharmaceuticals.
- the present invention has been made in view of the above circumstances, and can be used as a labeled precursor compound of a radiohalogen-labeled amino acid compound having a cyclobutane ring skeleton such as [ 18 F] FACBC, Another object of the present invention is to provide a novel amino acid organic compound without methanol remaining in the produced radiohalogen-labeled amino acid compound. Means for solving the problem
- the compound according to the present invention has the following formula (1):
- n is 0 or an integer of 1 to 4, and can take an appropriate value depending on the type of the radiohalogen-labeled amino acid compound that is the production target compound.
- the target compound is a compound in which the 3rd-position halogen is directly bonded to the cyclobutane ring (eg, [ 18 F] FACBC)
- the value of n is 0 and [ 18 F] 1 amino-3 It is 1 when the compound is bonded to the 3-position of the cyclobutane ring via a halogen power S methylene chain, such as fluoromethylcyclobutanecarboxylic acid.
- R 1 is an ethyl substituent, a 1 propyl substituent, or an isopropyl substituent, preferably an ethyl substituent.
- X is a halogen substituent or a group represented by OR 2
- R 2 is a linear or branched haloalkylsulfonic acid substituent having 1 to 10 carbon atoms, and 3 to 12 carbon atoms Selected from the group consisting of a trialkyl stannyl substituent, a fluorosulfonic acid substituent and an aromatic sulfonic acid substituent, and a toluenesulfonic acid substituent, a nitrobenzenesulfonic acid substituent, a benzenesulfonic acid substituent, A substituent selected from a lomethanesulfonic acid substituent, a fluorosulfonic acid substituent, a perfluoroalkylsulfonic acid substituent, a trimethylstanl substituent and a triethylstanl substituent can be preferably used.
- halogen substituent a bromo or chloro substituent can be preferably used.
- R 3 represents a linear or branched alkyloxycarbol substituent having 2 to 7 carbon atoms, a linear or branched alkoxycarboxyl substituent having 3 to 7 carbon atoms, or a modifying group.
- the compound according to the present invention can be used as a labeled precursor compound of a radiohalogen-labeled amino acid compound having a cyclobutane ring skeleton. Further, when the compound according to the present invention is used as a labeling precursor, there is an effect that residual methanol in the produced radiohalogen-labeled amino acid compound is suppressed.
- This syn-1 amino-3 benzyloxycyclobutane 1 rubonic acid is thoroughly dried to remove water and dissolved in ethanol, followed by addition of a base and further addition of salt. After adding nil and stirring at room temperature, the mixture is heated to reflux at a temperature of about 95 ° C. After the reaction has proceeded sufficiently, the solution is concentrated under reduced pressure to give syn-1 amino-3 benzyloxycyclobutane 1 carboxylic acid ethyl ester as white crystals (FIG. 1, step 2).
- the base to be added to the reaction solution triethylamine can be preferably used as long as it can trap hydrochloric acid generated during the reaction. The amount used should be equal to or greater than that of thionyl chloride.
- the amount of thiol chloride must be equal to or greater than the reaction raw material syn-1 amino-3 benzyloxycyclobutane 1 rubonic acid. At this time, if the amount of thiol chloride is small, the ethyl ester reaction does not proceed sufficiently, which is not preferable. Also, if the amount added is too large, more hydrochloric acid is generated, and it is necessary to use more base, which is not preferable. In a preferred embodiment, the amount of chlorothionyl is 5 equivalents or less based on syn-1-amino-3-benzyloxycyclobutane 1 carboxylic acid.
- syn-1 amino-3 benzyloxycyclobutane-1 cetyl ester rubonate was prepared in a solution containing a small amount of base in an alcohol solvent such as ethanol, and the resulting suspension was obtained.
- an alcohol solvent such as ethanol
- t-butyl dicarbonate and react at room temperature (Fig. 1, step 3).
- various alcohol solvents can be used, and ethanol can be preferably used.
- the amount of the base that needs to be sufficiently small relative to the alcohol is not preferable because the reaction will slow down if the amount is too small.
- the alcohol / base ratio is 9: 1.
- the amount of t-butyl dicarbonate needs to be equal to or greater than that of syn-1 amino-3 benzyloxycyclobutane 1 rubonic acid, preferably 1.5 equivalents.
- syn-1- (N- (t-butoxycarbol) amino) -3 benzyloxycyclobutane 1 mono-rubonic acid ethyl ester can be obtained.
- syn-1 1 (N- (t-butoxycarbo-l) amino) 3 benzyloxycyclobutane 1 synthesized in the above is used as an alcohol solvent such as ethanol or an acetate solvent such as ethyl acetate.
- alcohol solvent such as ethanol or an acetate solvent such as ethyl acetate.
- palladium-activated carbon (addition amount: 10 wZw% or more with respect to the substrate) is added under a hydrogen atmosphere, and the mixture is allowed to react at room temperature with stirring.
- the reaction solution is then filtered through Celite, and the filtrate is concentrated and purified.
- syn-1- (N- (t-butoxycarbol) amino) 3 hydroxy monocyclobutane 1 rubonic acid ethyl ester is obtained (FIG. 2, step 4).
- the amino group at the 1-position is bonded to an alkyloxycarbol substituent other than a t-butoxycarbol substituent, an alkoxycarboxyl substituent, and a benzyloxycarbol substituent.
- an alkyloxycarbol substituent other than a t-butoxycarbol substituent, an alkoxycarboxyl substituent, and a benzyloxycarbol substituent When synthesizing the compound, in Step 3 above, the reaction using various alkyl chloroformates, alkyl chloroformates or benzyl chloroformates instead of t-butyl dicarbonate is performed. Just do it.
- phthalic anhydride is synthesized.
- the alcohol to be reacted in Step 2 may be 1 propanol and isopropanol, respectively.
- the synthesis of anti- [ 18 F] FACBC is carried out in two steps: a step of adding radioactive fluorine to the precursor and a step of deprotecting the compound to which radioactive fluorine has been added.
- Radioactive fluorine is irradiated with protons using a known method, for example, H 180 concentrated water as a target.
- radioactive fluorine was used as a target.
- H 180 is present in concentrated water.
- H 180 concentrated water containing this radioactive fluorine for example,
- a potassium carbonate solution is passed through the column to elute the radioactive fluorine, and a phase transfer catalyst is added to dry the solid to activate the radioactive fluorine.
- the dried radioactive fluorine was dissolved in acetonitrile, and the precursor compound syn-l- (N— (t-butoxycarbol) amino) 3— [((trifluoromethyl ) Sulfo- (oxy) oxy] -cyclobutane 1
- the fluoric acid ethyl ester is added to the reaction mixture and heated to react with it.
- Radioactive fluorine is added to the precursor compound and anti- [ 18 F] 1-( N- (t-Butoxycarbol) amino) 3 Fluorocyclobutane 1
- a strong rubonic acid ethyl ester is synthesized.
- the obtained anti- [ 18 F] 1— (N— (t-butoxycarbol) amino) -3 fluorocyclobutane-1-carboxylic acid ethyl ester is obtained by, for example, applying deprotection under acidic conditions.
- Anti- [ 18 F] FACBC can be obtained.
- Acidic conditions can be provided by various methods, for example, anti- [ 18 F] 1— (N— (t-butoxycarbol) amino) 3 fluorocyclobutane 1 in a solution containing carboxylic acid ethyl ester. It can be given by adding an acid.
- the amount of acid to be added is not particularly limited as long as it is an amount that can provide sufficient acidic conditions for deprotection.
- a compound in which a trialkylstannyl substituent is bonded to the carbon at the 3-position of the cyclobutane ring is added with various radioactive halogens depending on the purpose and an oxidant, and reacted to react. It is possible to obtain a marker compound.
- a compound in which a halogen substituent is bonded to the carbon at the 3-position can be labeled with a radioactive or rogen using a nucleophilic substitution reaction or an isotope exchange reaction.
- radiohalogen labeling is performed by nucleophilic substitution reaction, the following substitution reaction can be performed.
- the halogen bonded to the 3-position carbon is iodine, it can be substituted with fluorine, chlorine, or bromine, when bromine is substituted with chlorine or fluorine, and when chlorine is substituted with fluorine.
- reaction solution was concentrated under reduced pressure to obtain white crystals as a residue.
- 150 mL of cold ethyl acetate and 150 mL of 0.5 mol ZL of cold hydrochloric acid were added, stirred for 5 minutes in an ice bath, and then allowed to stand and separate.
- the organic layer was extracted and washed in the order of 150 mL of water, 150 mL of saturated aqueous sodium hydrogen carbonate solution, 150 mL of water, 150 mL of water and 2, 150 mL of saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a yellow oil. Obtained.
- the aqueous layer was extracted and washed in the order of 150 mL ⁇ 2, 150 mL ⁇ 2, 150 mL of saturated brine and 150 mL of saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to recover a small amount of yellow oil. Through a series of operations, 8.82 g of a pale yellow oily substance was obtained.
- the solution was passed through an ion exchange column, and [ 18 F] fluoride ions were collected by adsorption. Then, an aqueous potassium carbonate solution to the column (133 mmol / LZ_ ⁇ . 3 mL) and 40 mg of crypto Huy ivy scan 222 (trade name, manufactured by Merck & Co., Inc.) was passed through a solution obtained by dissolving the Asetonitoriru 1.5 mL [18 F] fluoride ions were eluted.
- the compound of the present invention provides a radiohalogen-labeled organic compound used as a radiopharmaceutical in nuclear medicine examinations such as PET and SPECT, and is useful in radiopharmaceuticals.
Description
Claims
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2629227A CA2629227C (en) | 2005-11-29 | 2006-11-28 | Precursor compound of radioactive halogen-labeled organic compound |
EP18160037.0A EP3354639B1 (en) | 2005-11-29 | 2006-11-28 | Precursor compound of radioactive halogen-labeled organic compound |
ES06833463.0T ES2663496T3 (es) | 2005-11-29 | 2006-11-28 | Compuesto precursor de compuesto orgánico marcado con halógeno radiactivo |
NZ568179A NZ568179A (en) | 2005-11-29 | 2006-11-28 | Cyclobutane derivative as a precursor compound of radioactive halogen labeled organic compound |
JP2007547939A JP5635225B2 (ja) | 2005-11-29 | 2006-11-28 | 放射性ハロゲン標識有機化合物の前駆体化合物 |
EP06833463.0A EP1978015B1 (en) | 2005-11-29 | 2006-11-28 | Precursor compound of radioactive halogen labeled organic compound |
KR1020137022428A KR101643991B1 (ko) | 2005-11-29 | 2006-11-28 | 방사성 할로겐 표식 유기 화합물의 전구체 화합물 |
AU2006319987A AU2006319987B2 (en) | 2005-11-29 | 2006-11-28 | Precursor compound of radioactive halogen labeled organic compound |
KR1020147023255A KR101608755B1 (ko) | 2005-11-29 | 2006-11-28 | 방사성 할로겐 표식 유기 화합물의 전구체 화합물 |
BRPI0619213A BRPI0619213B8 (pt) | 2005-11-29 | 2006-11-28 | composto precursor de composto orgânico marcado com haloênio radioativo |
US12/085,679 US8758724B2 (en) | 2005-11-29 | 2006-11-28 | Unnatural amino acid radiolabeling precursor |
PL06833463T PL1978015T3 (pl) | 2005-11-29 | 2006-11-28 | Związek prekursorowy związku organicznego znakowanego radioaktywnym halogenem |
IL191184A IL191184A (en) | 2005-11-29 | 2008-05-01 | Cyclobutyl is converted as a parent compound to organic compounds tagged with radioactive halogen |
NO20082877A NO341981B1 (no) | 2005-11-29 | 2008-06-24 | Forløperforbindelse til radioaktive, halogenmerkede organiske forbindelser |
US14/246,594 US9381259B2 (en) | 2005-11-29 | 2014-04-07 | Precursor compound of radioactive halogen-labeled organic compound |
IL235029A IL235029A (en) | 2005-11-29 | 2014-10-07 | Method for Production of 1-Amino-3 - [18 f] Fluorocyclobutane Carboxylic Acid from a Marked Parent Compound |
US14/814,185 US9387266B2 (en) | 2005-11-29 | 2015-08-21 | Precursor compound of radioactive halogen-labeled organic compound |
US14/872,305 US10010632B2 (en) | 2005-11-29 | 2015-10-01 | Precursor compound of radioactive halogen-labeled organic compound |
NO20180010A NO20180010A1 (no) | 2005-11-29 | 2018-01-04 | Forløperforbindelse for radioaktive, halogenmerkede organiske forbindelser |
US15/977,522 US11083804B2 (en) | 2005-11-29 | 2018-05-11 | Precursor compound of radioactive halogen-labeled organic compound |
US16/852,910 US10953112B2 (en) | 2005-11-29 | 2020-04-20 | Precursor compound of radioactive halogen-labeled organic compound |
US17/356,757 US20210386873A1 (en) | 2005-11-29 | 2021-06-24 | Precursor compound of radioactive halogen-labeled organic compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005343653 | 2005-11-29 | ||
JP2005-343653 | 2005-11-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/085,679 A-371-Of-International US8758724B2 (en) | 2005-11-29 | 2006-11-28 | Unnatural amino acid radiolabeling precursor |
US14/246,594 Continuation US9381259B2 (en) | 2005-11-29 | 2014-04-07 | Precursor compound of radioactive halogen-labeled organic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007063824A1 true WO2007063824A1 (ja) | 2007-06-07 |
Family
ID=38092157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/323659 WO2007063824A1 (ja) | 2005-11-29 | 2006-11-28 | 放射性ハロゲン標識有機化合物の前駆体化合物 |
Country Status (17)
Country | Link |
---|---|
US (7) | US8758724B2 (ja) |
EP (2) | EP3354639B1 (ja) |
JP (2) | JP5635225B2 (ja) |
KR (3) | KR20080071146A (ja) |
CN (1) | CN101316812A (ja) |
AU (1) | AU2006319987B2 (ja) |
BR (1) | BRPI0619213B8 (ja) |
CA (1) | CA2629227C (ja) |
ES (1) | ES2663496T3 (ja) |
IL (2) | IL191184A (ja) |
NO (2) | NO341981B1 (ja) |
NZ (1) | NZ568179A (ja) |
PL (1) | PL1978015T3 (ja) |
PT (1) | PT1978015T (ja) |
RU (1) | RU2428415C2 (ja) |
TW (1) | TW200800869A (ja) |
WO (1) | WO2007063824A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008078589A1 (ja) * | 2006-12-27 | 2008-07-03 | Nihon Medi-Physics Co., Ltd. | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 |
JP2014509299A (ja) * | 2010-12-20 | 2014-04-17 | ジーイー・ヘルスケア・リミテッド | 前駆体化合物に対するプロセス簡略化 |
JP2014509303A (ja) * | 2010-12-20 | 2014-04-17 | ジーイー・ヘルスケア・リミテッド | 結晶化による前駆体化合物の精製 |
JP2014514268A (ja) * | 2011-03-08 | 2014-06-19 | ジーイー・ヘルスケア・リミテッド | Pet前駆体の製造 |
JP2017214389A (ja) * | 2010-12-20 | 2017-12-07 | ジーイー・ヘルスケア・リミテッド | 結晶化による前駆体化合物の精製 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130217908A1 (en) * | 2010-10-28 | 2013-08-22 | Ge Healthcare Limited | Stabilisation of radiopharmaceutical precursors |
KR20130140041A (ko) * | 2010-11-29 | 2013-12-23 | 지이 헬쓰케어 리미티드 | Pet 전구체의 제조 |
WO2012171941A1 (en) | 2011-06-14 | 2012-12-20 | Ge Healthcare Limited | Preparation of pet precursor |
DK2734494T3 (en) | 2011-07-21 | 2019-02-25 | Ge Healthcare Ltd | PRECURSOR RELATIONS AND PROCEDURES FOR PREPARING THE SAME |
JP6446268B2 (ja) * | 2011-12-21 | 2018-12-26 | ジーイー・ヘルスケア・リミテッド | クエン酸緩衝液中の18f−フルシクロビン組成物 |
GB201411569D0 (en) | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Novel formulation and method of synthesis |
US11534494B2 (en) | 2011-12-21 | 2022-12-27 | Ge Healthcare Limited | Formulation and method of synthesis |
JP6789991B2 (ja) * | 2015-06-04 | 2020-11-25 | 日本メジフィジックス株式会社 | 癌の早期骨転移の画像診断剤 |
US10513367B2 (en) * | 2016-02-12 | 2019-12-24 | Graphic Packaging International, Llc | Carton with handle |
AU2018232211A1 (en) * | 2017-03-07 | 2019-09-26 | Nihon Medi-Physics Co., Ltd. | Radioactive fluorine-labeling precursor compound and method for producing radioactive fluorine-labeled compound using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500442A (ja) | 1995-11-09 | 2000-01-18 | エモリー ユニバーシティ | 腫瘍画像化のためのアミノ酸アナログ |
WO2004056725A1 (en) * | 2002-12-20 | 2004-07-08 | Ge Healthcare Limited | Solid-phase preparation of 18f-labelled amino acids |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360928A (en) * | 1989-10-23 | 1994-11-01 | Research Corporation Technologies, Inc. | Synthesis and use of amino acid fluorides as peptide coupling reagents |
JP3722294B2 (ja) | 1993-02-23 | 2005-11-30 | ワーナー−ランバート・コンパニー | 実質的にアルコールを含有しない医薬組成物の製造方法 |
CN1309661A (zh) * | 1998-05-15 | 2001-08-22 | 尼科梅德阿默沙姆公开有限公司 | 标记的谷氨酰胺和赖氨酸类似物 |
AU8112101A (en) * | 2000-08-08 | 2002-02-18 | Ortho Mcneil Pharm Inc | Non-imidazole aryloxypiperidines |
WO2002030943A1 (fr) | 2000-10-12 | 2002-04-18 | Chugai Seiyaku Kabushiki Kaisha | Derive d'erythromycine possedant des nouvelles structures cristallines et procedes associes de production |
JP2005519861A (ja) | 2001-07-27 | 2005-07-07 | ターゲサム・インコーポレーテッド | 治療剤及び撮像剤としての脂質構築物 |
EP1660137A4 (en) | 2003-07-31 | 2008-11-12 | Univ St Louis | SIGMA 2 RECEPTOR RADIOACTIVE TRACTORS FOR IMAGING THE STATE OF PROLIFERATION OF SOLID TUMORS |
JP4979945B2 (ja) | 2003-09-30 | 2012-07-18 | 日本メジフィジックス株式会社 | 放射性フッ素化合物の製造方法 |
AU2005265164A1 (en) * | 2004-06-17 | 2006-01-26 | Musc Foundation For Research Development | Non-natural amino acids |
DK1889834T3 (da) * | 2005-05-23 | 2011-08-08 | Nihon Mediphysics Co Ltd | Ny organisk forbindelse og fremgangsmåde til at fremstille radioaktiv halogenmærket organisk forbindelse ved anvendelse af samme |
WO2007001940A2 (en) * | 2005-06-23 | 2007-01-04 | Emory University | Imaging agents |
EP1893246A4 (en) * | 2005-06-23 | 2009-05-06 | Univ Emory | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGUE FOR TUMOR IMAGING |
US7897811B2 (en) | 2006-05-11 | 2011-03-01 | Nihon Medi-Physics Co., Ltd. | Process for production of radioactive fluorine-labeled organic compound |
AU2007335633A1 (en) | 2006-12-21 | 2008-06-26 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
TWI402079B (zh) | 2006-12-27 | 2013-07-21 | Nihon Mediphysics Co Ltd | A method for producing a precursor compound of a radioactive halogen-labeled organic compound |
WO2008099800A1 (ja) | 2007-02-13 | 2008-08-21 | Nihon Medi-Physics Co., Ltd. | 放射性画像診断剤の製造方法 |
JP5732198B2 (ja) | 2007-12-19 | 2015-06-10 | 日本メジフィジックス株式会社 | 放射性フッ素標識有機化合物の製造方法 |
-
2006
- 2006-11-28 WO PCT/JP2006/323659 patent/WO2007063824A1/ja active Application Filing
- 2006-11-28 PL PL06833463T patent/PL1978015T3/pl unknown
- 2006-11-28 US US12/085,679 patent/US8758724B2/en active Active
- 2006-11-28 CA CA2629227A patent/CA2629227C/en active Active
- 2006-11-28 AU AU2006319987A patent/AU2006319987B2/en active Active
- 2006-11-28 EP EP18160037.0A patent/EP3354639B1/en active Active
- 2006-11-28 KR KR1020087012348A patent/KR20080071146A/ko active Search and Examination
- 2006-11-28 PT PT68334630T patent/PT1978015T/pt unknown
- 2006-11-28 JP JP2007547939A patent/JP5635225B2/ja active Active
- 2006-11-28 CN CNA2006800448187A patent/CN101316812A/zh active Pending
- 2006-11-28 BR BRPI0619213A patent/BRPI0619213B8/pt active IP Right Grant
- 2006-11-28 KR KR1020147023255A patent/KR101608755B1/ko active IP Right Grant
- 2006-11-28 TW TW095143886A patent/TW200800869A/zh unknown
- 2006-11-28 NZ NZ568179A patent/NZ568179A/en unknown
- 2006-11-28 ES ES06833463.0T patent/ES2663496T3/es active Active
- 2006-11-28 KR KR1020137022428A patent/KR101643991B1/ko active IP Right Grant
- 2006-11-28 RU RU2008126277/04A patent/RU2428415C2/ru active
- 2006-11-28 EP EP06833463.0A patent/EP1978015B1/en active Active
-
2008
- 2008-05-01 IL IL191184A patent/IL191184A/en active IP Right Grant
- 2008-06-24 NO NO20082877A patent/NO341981B1/no active Protection Beyond IP Right Term
-
2013
- 2013-06-26 JP JP2013133306A patent/JP5684333B2/ja active Active
-
2014
- 2014-04-07 US US14/246,594 patent/US9381259B2/en active Active
- 2014-10-07 IL IL235029A patent/IL235029A/en active IP Right Grant
-
2015
- 2015-08-21 US US14/814,185 patent/US9387266B2/en active Active
- 2015-10-01 US US14/872,305 patent/US10010632B2/en active Active
-
2018
- 2018-01-04 NO NO20180010A patent/NO20180010A1/no not_active Application Discontinuation
- 2018-05-11 US US15/977,522 patent/US11083804B2/en active Active
-
2020
- 2020-04-20 US US16/852,910 patent/US10953112B2/en active Active
-
2021
- 2021-06-24 US US17/356,757 patent/US20210386873A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500442A (ja) | 1995-11-09 | 2000-01-18 | エモリー ユニバーシティ | 腫瘍画像化のためのアミノ酸アナログ |
WO2004056725A1 (en) * | 2002-12-20 | 2004-07-08 | Ge Healthcare Limited | Solid-phase preparation of 18f-labelled amino acids |
Non-Patent Citations (7)
Title |
---|
JONATHAN MCCONATHY ET AL., APPLIED RADIATION AND ISOTOPES, vol. 58, 2003, pages 657 - 666 |
JONATHAN MCCONATHY ET AL.: "Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis", APPLIED RADIATION AND ISOTOPES, vol. 58, 2003, pages 657 - 666, XP055266777, DOI: doi:10.1016/S0969-8043(03)00029-0 |
MARTARELLO L. ET AL: "Synthesis of syn- and anti-1-Amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic Acid (FMACBC), Potential PET Ligands for Tumor Detection", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 11, 2002, pages 2250 - 2259, XP003013678 * |
See also references of EP1978015A4 |
THEODORA W. GREENE: "Protective groups in organic synthesi", vol. 531, 1999, WILEY & SONS, pages: 550 - 561. 573 |
TIMOTHY M. SHOUP ET AL.: "Synthesis and Evaluation of [18F]1-Amino-3-fluorocyclobutane-1-carboxylic Acid to Image Brain Tumors", THE JOURNAL OF NUCLEAR MEDICINE, vol. 40, 1999, pages 331 - 338 |
WANG L.J. ET AL: "Syntheses of new conformationally constrained S-[2-[(1-iminoethyl)amino] ethyl]homocysteine derivatives as potential nitric oxide synthase inhibitors", HETEROATOM CHEMISTRY, vol. 13, no. 1, 2002, pages 77 - 83, XP003013677 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008078589A1 (ja) * | 2006-12-27 | 2008-07-03 | Nihon Medi-Physics Co., Ltd. | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 |
US8563771B2 (en) | 2006-12-27 | 2013-10-22 | Nihon Medi-Physics Co., Ltd. | Process for production of precursor compound for radioactive halogen-labeled organic compound |
JP2014509299A (ja) * | 2010-12-20 | 2014-04-17 | ジーイー・ヘルスケア・リミテッド | 前駆体化合物に対するプロセス簡略化 |
JP2014509303A (ja) * | 2010-12-20 | 2014-04-17 | ジーイー・ヘルスケア・リミテッド | 結晶化による前駆体化合物の精製 |
JP2017214389A (ja) * | 2010-12-20 | 2017-12-07 | ジーイー・ヘルスケア・リミテッド | 結晶化による前駆体化合物の精製 |
JP2014514268A (ja) * | 2011-03-08 | 2014-06-19 | ジーイー・ヘルスケア・リミテッド | Pet前駆体の製造 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007063824A1 (ja) | 放射性ハロゲン標識有機化合物の前駆体化合物 | |
JP4550141B2 (ja) | 放射性フッ素標識有機化合物の製造方法 | |
JP5732198B2 (ja) | 放射性フッ素標識有機化合物の製造方法 | |
TWI410396B (zh) | A new method for the production of organic compounds and the use of the compounds for radioactive halogen calibration of organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680044818.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006833463 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 191184 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2629227 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4001/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 568179 Country of ref document: NZ Ref document number: 2007547939 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087012348 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12085679 Country of ref document: US Ref document number: 2006319987 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006319987 Country of ref document: AU Date of ref document: 20061128 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008126277 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0619213 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080529 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137022428 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147023255 Country of ref document: KR |